Financials

  • Market Capitalization 400.55 M
  • Employee 45
  • Founded 2019
  • CEO N/A
  • Website www.x4pharma.com
  • Headquarter Delaware, United States
  • FIGI BBG001J1CYH8
  • Industry Biotecnologia
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
3.68
Rapporto prezzo/fatturato
35.88

Related tickers

#NomePrezzo24h %7d %1M %1Y %Valore di MercatoUltimi 7 Giorni
3050
LRMR
Larimar Therapeutics, Inc. - Common Stock
4.01 USD-0.99%-5.20%+4.97%+9.56%416.57 M USD
3069
GALT
Galectin Therapeutics Inc. - Common Stock
4.02 USD-2.90%+9.24%+23.31%-6.07%405.42 M USD
3079
LXEO
Lexeo Therapeutics, Inc. - Common Stock
4.86 USD-2.61%-0.41%+10.96%+1.89%398.74 M USD
3085
ENTA
Enanta Pharmaceuticals, Inc. - Common Stock
13.60 USD-1.45%+1.19%+4.78%+56.32%396.11 M USD

Notizie